These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6831629)

  • 1. Increased uptake of actinomycin D in Ehrlich ascites tumour cells induced by daunorubicin.
    Lund-Andersen C; Skovsgaard T; Nissen NI
    Cancer Chemother Pharmacol; 1983; 10(2):79-83. PubMed ID: 6831629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
    Seeber S; Loth H; Crooke ST
    J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibitor interaction in the suppression of ribosomal RNA synthesis in Ehrlich ascites carcinoma cells].
    Akhlynina TV; Buzhurina IM; Panov MA; Rozovskaia IA; Chernaia IG
    Tsitologiia; 1984 Nov; 26(11):1313-8. PubMed ID: 6523576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.
    Skovsgaard T
    Cancer Chemother Pharmacol; 1979; 2(1):43-7. PubMed ID: 498419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystostatic efficacy of DNA-complexes of adriamycin, daunomycin, and actinomycin D. II. Comparative in vivo studies in an Ehrlich-ascites tumor.
    Seeber S; Schilcher RB; Brucksch KP; Käding J; Schmidt CG
    Z Krebsforsch Klin Onkol Cancer Res Clin Oncol; 1977 Dec; 90(3):307-12. PubMed ID: 146332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.
    Inaba M; Johnson RK
    Cancer Res; 1977 Dec; 37(12):4629-34. PubMed ID: 922743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of actinomycin D on purine ribonucleotide metabolism in Ehrlich ascites tumor cells in vitro.
    Snyder FF; Henderson JF
    Can J Biochem; 1974 Mar; 52(3):263-7. PubMed ID: 4364138
    [No Abstract]   [Full Text] [Related]  

  • 8. P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin.
    Nielsen D; Eriksen J; Maare C; Jakobsen AH; Skovsgaard T
    Br J Cancer; 1998 Nov; 78(9):1175-80. PubMed ID: 9820176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship among transport, intracellular binding, and inhibition of RNA synthesis by actinomycin D in Ehrlich ascites tumor cells in vitro.
    Bowen D; Goldman ID
    Cancer Res; 1975 Nov; 35(11 Pt 1):3054-60. PubMed ID: 1182700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of anthracycline-induced degradation of nuclear DNA in Ehrlich ascites tumour cells.
    Velcich A; di Marco A; Colombo A; Zunino F
    Chem Biol Interact; 1979 Jan; 24(1):95-106. PubMed ID: 85499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Jun; 38(6):1785-91. PubMed ID: 647687
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129.
    Meador J; Sweet P; Stupecky M; Wetzel M; Murray S; Gupta S; Slater L
    Cancer Res; 1987 Dec; 47(23):6216-9. PubMed ID: 3677073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
    Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
    Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.
    Skovsgaard T
    Cancer Chemother Rep; 1975; 59(2 Pt 1):301-8. PubMed ID: 1149008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.
    Slater LM; Murray SL; Wetzel MW; Wisdom RM; DuVall EM
    J Clin Invest; 1982 Nov; 70(5):1131-4. PubMed ID: 6182160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Dec; 38(12):4722-7. PubMed ID: 719649
    [No Abstract]   [Full Text] [Related]  

  • 17. [THE EFFECT OF ACTINOMYCIN D ON THE INCORPORATION OF LABELED AMINO ACIDS INTO THE PROTEINS OF EHRLICH ASCITES CARCINOMA NUCLEI].
    ZBARSKII IB; GAUZE GG
    Vopr Med Khim; 1964; 10():446-7. PubMed ID: 14251734
    [No Abstract]   [Full Text] [Related]  

  • 18. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1977 Feb; 26(3):215-22. PubMed ID: 14644
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
    Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues.
    Friche E; Jensen PB; Roed H; Skovsgaard T; Nissen NI
    Biochem Pharmacol; 1990 Jun; 39(11):1721-6. PubMed ID: 2344368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.